{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T09:03:34Z","timestamp":1785402214579,"version":"3.56.0"},"reference-count":214,"publisher":"MDPI AG","issue":"12","license":[{"start":{"date-parts":[[2026,6,7]],"date-time":"2026-06-07T00:00:00Z","timestamp":1780790400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010653","name":"Masaryk University","doi-asserted-by":"publisher","award":["MUNI\/A\/1698\/2025"],"award-info":[{"award-number":["MUNI\/A\/1698\/2025"]}],"id":[{"id":"10.13039\/501100010653","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010653","name":"Masaryk University","doi-asserted-by":"publisher","award":["FM MU MUNI\/11\/PU\/1\/2025"],"award-info":[{"award-number":["FM MU MUNI\/11\/PU\/1\/2025"]}],"id":[{"id":"10.13039\/501100010653","id-type":"DOI","asserted-by":"publisher"}]},{"award":["MUNI\/A\/1698\/2025"],"award-info":[{"award-number":["MUNI\/A\/1698\/2025"]}],"id":[{"id":"https:\/\/ror.org\/02j46qs45","id-type":"ROR","asserted-by":"publisher"}]},{"award":["FM MU MUNI\/11\/PU\/1\/2025"],"award-info":[{"award-number":["FM MU MUNI\/11\/PU\/1\/2025"]}],"id":[{"id":"https:\/\/ror.org\/02j46qs45","id-type":"ROR","asserted-by":"publisher"}]},{"name":"University Hospital Brno","award":["DRO FNBr 65269705"],"award-info":[{"award-number":["DRO FNBr 65269705"]}]},{"award":["DRO FNBr 65269705"],"award-info":[{"award-number":["DRO FNBr 65269705"]}],"id":[{"id":"https:\/\/ror.org\/00qq1fp34","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"publisher","award":["Program EXCELES, ID Project No. LX22NPO5102"],"award-info":[{"award-number":["Program EXCELES, ID Project No. LX22NPO5102"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"award":["Program EXCELES, ID Project No. LX22NPO5102"],"award-info":[{"award-number":["Program EXCELES, ID Project No. LX22NPO5102"]}],"id":[{"id":"https:\/\/ror.org\/019w4f821","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003243","name":"Ministry of Health","doi-asserted-by":"publisher","award":["NW26-03-00001"],"award-info":[{"award-number":["NW26-03-00001"]}],"id":[{"id":"10.13039\/501100003243","id-type":"DOI","asserted-by":"publisher"}]},{"award":["NW26-03-00001"],"award-info":[{"award-number":["NW26-03-00001"]}],"id":[{"id":"https:\/\/ror.org\/00y6khe77","id-type":"ROR","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006704","name":"University of Ostrava","doi-asserted-by":"publisher","award":["SGS09\/LF\/2025"],"award-info":[{"award-number":["SGS09\/LF\/2025"]}],"id":[{"id":"10.13039\/501100006704","id-type":"DOI","asserted-by":"publisher"}]},{"award":["SGS09\/LF\/2025"],"award-info":[{"award-number":["SGS09\/LF\/2025"]}],"id":[{"id":"https:\/\/ror.org\/00pyqav47","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Waldenstr\u00f6m macroglobulinemia is a rare lymphoplasmacytic malignancy characterized by bone marrow infiltration and monoclonal immunoglobulin M production. Despite its indolent clinical course, the disease exhibits considerable biological complexity driven by recurrent genetic alterations, dysregulated signaling pathways, and a supportive bone marrow microenvironment. The identification of MYD88 and CXCR4 mutations has significantly advanced understanding of disease pathogenesis, clonal evolution, and treatment response. Additional insights from cytogenetic, epigenetic, and microRNA studies have further refined the molecular landscape of this disorder. These advances have translated into improved therapeutic strategies, particularly with the introduction of Bruton\u2019s tyrosine kinase inhibitors, although treatment resistance remains a clinical challenge. Other targeted approaches, including BCL2 and proteasome inhibition, offer additional options for personalized therapy. Ongoing integration of molecular and microenvironmental data is expected to enhance risk stratification and support the development of more effective, tailored treatment strategies.<\/jats:p>","DOI":"10.3390\/ijms27125173","type":"journal-article","created":{"date-parts":[[2026,6,8]],"date-time":"2026-06-08T05:43:46Z","timestamp":1780897426000},"page":"5173","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Decoding Waldenstr\u00f6m Macroglobulinemia Through Genomics, Epigenomics and Cellular Interactions"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0009-0002-5758-7087","authenticated-orcid":false,"given":"Tereza","family":"R\u016f\u017ei\u010dkov\u00e1","sequence":"first","affiliation":[{"name":"Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic"},{"name":"Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, 625 00 Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michal","family":"Ka\u0161\u010d\u00e1k","sequence":"additional","affiliation":[{"name":"Department of Hematooncology, University Hospital Ostrava, 708 00 Ostrava, Czech Republic"},{"name":"Department of Hematooncology, Faculty of Medicine, University of Ostrava, 702 00 Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuzana","family":"Chyra","sequence":"additional","affiliation":[{"name":"Department of Hematooncology, University Hospital Ostrava, 708 00 Ostrava, Czech Republic"},{"name":"Department of Hematooncology, Faculty of Medicine, University of Ostrava, 702 00 Ostrava, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viera","family":"Sandeck\u00e1","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Hematology and Oncology, University Hospital Brno, 625 00 Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jana","family":"Kota\u0161kov\u00e1","sequence":"additional","affiliation":[{"name":"Department of Hematooncology, University Hospital Ostrava, 708 00 Ostrava, Czech Republic"},{"name":"Institute of Medical Genetics and Genomics, University Hospital Brno, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7194-6771","authenticated-orcid":false,"given":"Sabina","family":"\u0160ev\u010d\u00edkov\u00e1","sequence":"additional","affiliation":[{"name":"Babak Myeloma Group, Department of Pathophysiology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,6,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1111\/j.0954-6820.1944.tb03955.x","article-title":"Incipient Myelomatosis or \u00abessential\u00bb Hyperglobulinemia with Fibrinogenopenia\u2014A New Syndrome?","volume":"117","year":"1944","journal-title":"Acta Med. Scand."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.mayocp.2018.02.011","article-title":"Fifty-Year Incidence of Waldenstr\u00f6m Macroglobulinemia in Olmsted County, Minnesota, from 1961 Through 2010: A Population-Based Study with Complete Case Capture and Hematopathologic Review","volume":"93","author":"Kyle","year":"2018","journal-title":"Mayo Clin. Proc."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1053\/j.seminhematol.2023.03.008","article-title":"The Epidemiology of Waldenstr\u00f6m Macroglobulinemia","volume":"60","author":"McMaster","year":"2023","journal-title":"Semin. Hematol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Boutilier, A.J., Huang, L., and Elsawa, S.F. (2022). Waldenstr\u00f6m Macroglobulinemia: Mechanisms of Disease Progression and Current Therapies. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms231911145"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/bjh.12102","article-title":"Response Assessment in W Aldenstr\u00f6m Macroglobulinaemia: Update from the VI Th I Nternational W Orkshop","volume":"160","author":"Owen","year":"2013","journal-title":"Br. J. Haematol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"101129","DOI":"10.1016\/j.blre.2023.101129","article-title":"Current Approach to Waldenstr\u00f6m Macroglobulinemia","volume":"62","author":"Kapoor","year":"2023","journal-title":"Blood Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th Edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2147\/BLCTT.S259860","article-title":"Differential Diagnosis of Waldenstr\u00f6m\u2019s Macroglobulinemia and Early Management: Perspectives from Clinical Practice","volume":"12","author":"Cingam","year":"2022","journal-title":"Blood Lymphat. Cancer Targets Ther."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 Revision of the World Health Organization Classification of Lymphoid Neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"100999","DOI":"10.1016\/j.blre.2022.100999","article-title":"The Use of Bone-Modifying Agents in Multiple Myeloma","volume":"57","author":"Hussain","year":"2023","journal-title":"Blood Rev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1002\/ajh.26796","article-title":"Waldenstr\u00f6m Macroglobulinemia: 2023 Update on Diagnosis, Risk Stratification, and Management","volume":"98","author":"Gertz","year":"2023","journal-title":"Am. J. Hematol."},{"key":"ref_12","first-page":"e247024","article-title":"Diagnosis and Risk Stratification in Waldenstr\u00f6m Macroglobulinemia","volume":"22","author":"Zanwar","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1111\/bjh.17856","article-title":"Primary Therapy and Relative Survival in Patients with Lymphoplasmacytic Lymphoma\/Waldenstr\u00f6m Macroglobulinaemia: A Population-based Study in the Netherlands, 1989\u20132018","volume":"196","author":"Amaador","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1007\/s11864-021-00890-9","article-title":"How to Sequence Therapies in Waldenstr\u00f6m Macroglobulinemia","volume":"22","author":"Sarosiek","year":"2021","journal-title":"Curr. Treat. Options Oncol."},{"key":"ref_15","first-page":"e240001","article-title":"Waldenstr\u00f6m Macroglobulinemia\/Lymphoplasmacytic Lymphoma, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology","volume":"22","author":"Kumar","year":"2024","journal-title":"J. Natl. Compr. Cancer Netw. JNCCN"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1200\/JCO.19.02314","article-title":"Genomic Landscape of Waldenstr\u00f6m Macroglobulinemia and Its Impact on Treatment Strategies","volume":"38","author":"Treon","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/s41375-022-01732-9","article-title":"Managing Waldenstr\u00f6m\u2019s Macroglobulinemia with BTK Inhibitors","volume":"37","author":"Buske","year":"2023","journal-title":"Leukemia"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1002\/ajh.26339","article-title":"Cytogenetic and Molecular Abnormalities in Waldenstr\u00f6m\u2019s Macroglobulinemia Patients: Correlations and Prognostic Impact","volume":"96","author":"Krzisch","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1200\/JCO.20.00555","article-title":"Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients with Waldenstr\u00f6m Macroglobulinemia","volume":"39","author":"Treon","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.hoc.2018.05.005","article-title":"The Bone Marrow Microenvironment in Waldenstr\u00f6m Macroglobulinemia","volume":"32","author":"Jalali","year":"2018","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1053\/sonc.2003.50051","article-title":"Asymptomatic Waldenstrom\u2019s Macroglobulinemia","volume":"30","author":"Alexanian","year":"2003","journal-title":"Semin. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"824","DOI":"10.4065\/mcp.2010.0304","article-title":"Diagnosis and Management of Waldenstr\u00f6m Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines","volume":"85","author":"Ansell","year":"2010","journal-title":"Mayo Clin. Proc."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1046\/j.1365-2141.2001.03144.x","article-title":"Waldenstr\u00f6m Macroglobulinaemia: Presenting Features and Outcome in a Series with 217 Cases","volume":"115","author":"Montoto","year":"2001","journal-title":"Br. J. Haematol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1182\/bloodadvances.2021004926","article-title":"Clonal Hematopoiesis Is Associated with Increased Risk of Progression of Asymptomatic Waldenstr\u00f6m Macroglobulinemia","volume":"6","author":"Tahri","year":"2022","journal-title":"Blood Adv."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.neo.2021.02.002","article-title":"Molecular and Genetic Biomarkers Implemented from Next-Generation Sequencing Provide Treatment Insights in Clinical Practice for Waldenstr\u00f6m Macroglobulinemia","volume":"23","author":"Wang","year":"2021","journal-title":"Neoplasia"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3816\/CLML.2011.n.038","article-title":"Hepcidin Is Produced by Lymphoplasmacytic Cells and Is Associated with Anemia in Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"11","author":"Ciccarelli","year":"2011","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1002\/ajh.27666","article-title":"Waldenstr\u00f6m Macroglobulinemia: 2025 Update on Diagnosis, Risk Stratification, and Management","volume":"100","author":"Gertz","year":"2025","journal-title":"Am. J. Hematol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"100648","DOI":"10.1016\/j.blre.2019.100648","article-title":"Diagnosis and Treatment of Autoimmune Hemolytic Anemia in Adults: Recommendations from the First International Consensus Meeting","volume":"41","author":"Barcellini","year":"2020","journal-title":"Blood Rev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.clml.2013.02.016","article-title":"Patients with Waldenstr\u00f6m Macroglobulinemia Commonly Present with Iron Deficiency and Those with Severely Depressed Transferrin Saturation Levels Show Response to Parenteral Iron Administration","volume":"13","author":"Treon","year":"2013","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.hemonc.2019.05.002","article-title":"Updates in Prognostication and Treatment of Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"12","author":"Advani","year":"2019","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2147\/JBM.S267938","article-title":"Waldenstr\u00f6m\u2019s Macroglobulinemia: An Exploration into the Pathology and Diagnosis of a Complex B-Cell Malignancy","volume":"12","author":"Askari","year":"2021","journal-title":"J. Blood Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1805","DOI":"10.1080\/10428194.2021.1881514","article-title":"Clinical Application of Genomics in Waldenstr\u00f6m Macroglobulinemia","volume":"62","author":"Branagan","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/j.hoc.2023.04.008","article-title":"Evaluation and Management of Bing-Neel Syndrome","volume":"37","author":"Schep","year":"2023","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/jha2.1037","article-title":"Extramedullary Disease in Waldenstr\u00f6m Macroglobulinemia: A Population-Based Observational Study","volume":"5","author":"Munksgaard","year":"2024","journal-title":"EJHaem"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2009-05-174359","article-title":"How I Treat Waldenstr\u00f6m Macroglobulinemia","volume":"114","author":"Treon","year":"2009","journal-title":"Blood"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"e2018004","DOI":"10.4084\/mjhid.2018.004","article-title":"Waldenstrom\u2019s Macroglobulinemia: An Update","volume":"10","author":"Mazzucchelli","year":"2018","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_37","unstructured":"Perez Rogers, A., and Estes, M. (2025). Hyperviscosity Syndrome. StatPearls, StatPearls Publishing."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1111\/trf.18152","article-title":"Hyperviscosity Syndrome in Waldenstr\u00f6m Macroglobulinemia","volume":"65","year":"2025","journal-title":"Transfusion"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Weaver, A., Rubinstein, S., and Cornell, R.F. (2020). Hyperviscosity Syndrome in Paraprotein Secreting Conditions Including Waldenstrom Macroglobulinemia. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.00815"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1017\/S0317167100011483","article-title":"The Neuropathies of Waldenstr\u00f6m\u2019s Macroglobulinemia (WM) and IgM-MGUS","volume":"38","author":"Klein","year":"2011","journal-title":"Can. J. Neurol. Sci. J. Can. Sci. Neurol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1182\/blood.V62.2.280.280","article-title":"Waldenstr\u00f6m\u2019s Macroglobulinemia and Peripheral Neuropathy: A Clinical and Immunologic Study of 25 Patients","volume":"62","author":"Dellagi","year":"1983","journal-title":"Blood"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1002\/ana.410220614","article-title":"Peripheral Neuropathy Associated with Monoclonal IgM Autoantibody","volume":"22","author":"Steck","year":"1987","journal-title":"Ann. Neurol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1053\/j.seminhematol.2023.03.002","article-title":"Report of Consensus Panel 6 from the 11 Th International Workshop on Waldenstr\u00f6m\u2019s Macroglobulinemia on Management of Waldenstr\u00f6m\u2019s Macroglobulinemia Related Amyloidosis","volume":"60","author":"Merlini","year":"2023","journal-title":"Semin. Hematol."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1038\/s41375-018-0286-7","article-title":"Primary Systemic Amyloidosis in Patients with Waldenstr\u00f6m Macroglobulinemia","volume":"33","author":"Zanwar","year":"2019","journal-title":"Leukemia"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1182\/blood-2020-136558","article-title":"Neuropathy with IgM Gammopathy: Incidence, Characteristics and Management, a Rory Morrison W.M.U.K Registry Analysis","volume":"136","author":"Tomkins","year":"2020","journal-title":"Blood"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"8114","DOI":"10.1200\/jco.2010.28.15_suppl.8114","article-title":"Clinical Characteristics and Treatment Outcome of Disease-Related Peripheral Neuropathy in Waldenstrom\u2019s Macroglobulinemia (WM)","volume":"28","author":"Treon","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0022-1759(91)90123-W","article-title":"Anti-Myelin-Associated Glycoprotein Antibodies in Patients with a Monoclonal IgM Gammopathy and Polyneuropathy, and a Simplified Method for the Preparation of Glycolipid Antigens","volume":"140","author":"Burger","year":"1991","journal-title":"J. Immunol. Methods"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1093\/brain\/117.5.949","article-title":"The Natural History of Chronic Demyelinating Neuropathy Associated with Benign IgM Paraproteinaemia. A Clinical and Neurophysiological Study","volume":"117","author":"Smith","year":"1994","journal-title":"Brain J. Neurol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.semarthrit.2007.04.001","article-title":"Schnitzler Syndrome: Beyond the Case Reports: Review and Follow-Up of 94 Patients with an Emphasis on Prognosis and Treatment","volume":"37","author":"Bodar","year":"2007","journal-title":"Semin. Arthritis Rheum."},{"key":"ref_50","first-page":"6","article-title":"Schnitzler Syndrome","volume":"76","author":"Gellrich","year":"2019","journal-title":"Hautarzt Z. Dermatol. Venerol. Verwandte Geb."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1111\/all.12030","article-title":"How Not to Miss Autoinflammatory Diseases Masquerading as Urticaria","volume":"67","author":"Krause","year":"2012","journal-title":"Allergy"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3816\/CLM.2005.n.011","article-title":"Prognostic Factors and Predictors of Outcome of Immunoglobulin M Monoclonal Gammopathy of Undetermined Significance","volume":"5","author":"Kyle","year":"2005","journal-title":"Clin. Lymphoma"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"2449","DOI":"10.1158\/0008-5472.CAN-17-3115","article-title":"From MGUS to Multiple Myeloma, a Paradigm for Clonal Evolution of Premalignant Cells","volume":"78","author":"Spaan","year":"2018","journal-title":"Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"e2023061","DOI":"10.4084\/MJHID.2024.061","article-title":"Waldenstr\u00f6m Macroglobulinemia\u2014A State-of-the-Art Review: Part 1: Epidemiology, Pathogenesis, Clinicopathologic Characteristics, Differential Diagnosis, Risk Stratification, and Clinical Problems","volume":"16","author":"Bibas","year":"2024","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1182\/blood.2022015851","article-title":"The International Consensus Classification of Mature Lymphoid Neoplasms: A Report from the Clinical Advisory Committee","volume":"140","author":"Campo","year":"2022","journal-title":"Blood"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1111\/bjh.15049","article-title":"MYD 88 Wild-type Waldenstrom Macroglobulinaemia: Differential Diagnosis, Risk of Histological Transformation, and Overall Survival","volume":"180","author":"Treon","year":"2018","journal-title":"Br. J. Haematol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1182\/blood-2014-09-602565","article-title":"The Cellular Origin and Malignant Transformation of Waldenstr\u00f6m Macroglobulinemia","volume":"125","author":"Paiva","year":"2015","journal-title":"Blood"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.leukres.2004.12.008","article-title":"Lymphoplasmacytic Lymphoma\/Waldenstr\u00f6m\u2019s Macroglobulinemia Derives from an Extensively Hypermutated B Cell That Lacks Ongoing Somatic Hypermutation","volume":"29","author":"Walsh","year":"2005","journal-title":"Leuk. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1053\/j.seminhematol.2023.03.009","article-title":"Report of Consensus Panel 4 from the 11th International Workshop on Waldenstrom\u2019s Macroglobulinemia on Diagnostic and Response Criteria","volume":"60","author":"Treon","year":"2023","journal-title":"Semin. Hematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1111\/bjh.14196","article-title":"Recommendations for the Diagnosis and Initial Evaluation of Patients with Waldenstr\u00f6m Macroglobulinaemia: A Task Force from the 8th International Workshop on Waldenstr\u00f6m Macroglobulinaemia","volume":"175","author":"Castillo","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2022","DOI":"10.1182\/blood.2019000725","article-title":"How I Treat Waldenstr\u00f6m Macroglobulinemia","volume":"134","author":"Dimopoulos","year":"2019","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1080\/17474086.2023.2270779","article-title":"New Developments in the Diagnosis and Characterization of Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"16","author":"Hunter","year":"2023","journal-title":"Expert Rev. Hematol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"104856","DOI":"10.1016\/j.isci.2022.104856","article-title":"Plasma Cells Arise from Differentiation of Clonal Lymphocytes and Secrete IgM in Waldenstr\u00f6m Macroglobulinemia","volume":"25","author":"Lim","year":"2022","journal-title":"iScience"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"e617","DOI":"10.1038\/bcj.2017.90","article-title":"Current Applications of Multiparameter Flow Cytometry in Plasma Cell Disorders","volume":"7","author":"Jelinek","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1038\/modpathol.2009.34","article-title":"Novel Immunophenotypic Features of Marrow Lymphoplasmacytic Lymphoma and Correlation with Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"22","author":"Morice","year":"2009","journal-title":"Mod. Pathol."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1053\/sonc.2003.50082","article-title":"Clinicopathological Definition of Waldenstrom\u2019s Macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom\u2019s Macroglobulinemia","volume":"30","author":"Owen","year":"2003","journal-title":"Semin. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.clml.2017.02.028","article-title":"Waldenstr\u00f6m Macroglobulinemia: Review of Pathogenesis and Management","volume":"17","author":"Yun","year":"2017","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e70620","DOI":"10.1111\/jcmm.70620","article-title":"Phenotypic Profile of Waldenstr\u00f6m Macroglobulinaemia B-Cells: Establishment of a Diagnosis Scoring System and Clinico-Biological Correlations","volume":"29","author":"Sourdeau","year":"2025","journal-title":"J. Cell. Mol. Med."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/leu.2013.124","article-title":"Multiparameter Flow Cytometry for the Identification of the Waldenstr\u00f6m\u2019s Clone in IgM-MGUS and Waldenstr\u00f6m\u2019s Macroglobulinemia: New Criteria for Differential Diagnosis and Risk Stratification","volume":"28","author":"Paiva","year":"2014","journal-title":"Leukemia"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1158\/1078-0432.CCR-22-2215","article-title":"Molecular Clusters and Tumor-Immune Drivers of IgM Monoclonal Gammopathies","volume":"29","author":"Mondello","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/blood.2023023639","article-title":"Multiomics Analysis of IgM Monoclonal Gammopathies Reveals Epigenetic Influence on Oncogenesis via DNA Methylation","volume":"144","author":"Chohan","year":"2024","journal-title":"Blood"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"101305","DOI":"10.1016\/j.blre.2025.101305","article-title":"Tackling Myeloma Bone Disease: From Pathophysiology to Cutting-Edge Therapies","volume":"74","author":"Roux","year":"2025","journal-title":"Blood Rev."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1182\/blood.V106.11.980.980","article-title":"Bone Marrow Mast Cells Are Significantly Increased in Patients with Waldenstrom\u2019s Macroglobulinemia, and Their Number Following Therapeutic Intervention Is Dependent on Extent of Response","volume":"106","author":"Santos","year":"2005","journal-title":"Blood"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1002\/jha2.378","article-title":"Mast Cell Density and Its Clinical Relevance in Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"3","author":"Lemal","year":"2022","journal-title":"EJHaem"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1093\/annonc\/mdl109","article-title":"Mast Cells in Waldenstrom\u2019s Macroglobulinemia Support Lymphoplasmacytic Cell Growth through CD154\/CD40 Signaling","volume":"17","author":"Tournilhac","year":"2006","journal-title":"Ann. Oncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1172\/JCI88169","article-title":"Blocking IFNAR1 Inhibits Multiple Myeloma\u2013Driven Treg Expansion and Immunosuppression","volume":"128","author":"Kawano","year":"2018","journal-title":"J. Clin. Investig."},{"key":"ref_77","first-page":"2615","article-title":"Targeting the Immune Microenvironment in Waldenstr\u00f6m Macroglobulinemia via Halting the CD40\/CD40-Ligand Axis","volume":"141","author":"Sacco","year":"2023","journal-title":"Blood"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1038\/s41467-025-56323-w","article-title":"Single-Cell RNA Sequencing Defines Distinct Disease Subtypes and Reveals Hypo-Responsiveness to Interferon in Asymptomatic Waldenstrom\u2019s Macroglobulinemia","volume":"16","author":"Konishi","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1158\/1078-0432.CCR-11-0111","article-title":"Eph-B2\/Ephrin-B2 Interaction Plays a Major Role in the Adhesion and Proliferation of Waldenstrom\u2019s Macroglobulinemia","volume":"18","author":"Azab","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1158\/2643-3230.BCD-21-0043","article-title":"Aberrant Extrafollicular B Cells, Immune Dysfunction, Myeloid Inflammation, and MyD88-Mutant Progenitors Precede Waldenstrom Macroglobulinemia","volume":"2","author":"Kaushal","year":"2021","journal-title":"Blood Cancer Discov."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/nature09671","article-title":"Oncogenically Active MYD88 Mutations in Human Lymphoma","volume":"470","author":"Ngo","year":"2011","journal-title":"Nature"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s41586-022-04558-8","article-title":"A Joint NCBI and EMBL-EBI Transcript Set for Clinical Genomics and Research","volume":"604","author":"Morales","year":"2022","journal-title":"Nature"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMc1506192","article-title":"MYD88 Mutations and Response to Ibrutinib in Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"373","author":"Treon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1182\/blood-2013-09-525808","article-title":"The Genomic Landscape of Waldenstr\u00f6m Macroglobulinemia Is Characterized by Highly Recurring MYD88 and WHIM-like CXCR4 Mutations, and Small Somatic Deletions Associated with B-Cell Lymphomagenesis","volume":"123","author":"Hunter","year":"2014","journal-title":"Blood"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.2016.71.0814","article-title":"Genomics, Signaling, and Treatment of Waldenstr\u00f6m Macroglobulinemia","volume":"35","author":"Hunter","year":"2017","journal-title":"J. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1182\/blood-2012-09-454355","article-title":"MYD88 L265P in Waldenstr\u00f6m Macroglobulinemia, Immunoglobulin M Monoclonal Gammopathy, and Other B-Cell Lymphoproliferative Disorders Using Conventional and Quantitative Allele-Specific Polymerase Chain Reaction","volume":"121","author":"Xu","year":"2013","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"dmm050227","DOI":"10.1242\/dmm.050227","article-title":"Clonal Architecture and Evolutionary History of Waldenstr\u00f6m\u2019s Macroglobulinemia at the Single-Cell Level","volume":"16","author":"Medina","year":"2023","journal-title":"Dis. Model. Mech."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1182\/blood.2024028164","article-title":"A Multiomic Analysis of Waldenstr\u00f6m Macroglobulinemia Defines Distinct Disease Subtypes","volume":"146","author":"Gagler","year":"2025","journal-title":"Blood"},{"key":"ref_89","first-page":"585","article-title":"Identification of 2 DNA Methylation Subtypes of Waldenstr\u00f6m Macroglobulinemia with Plasma and Memory B-Cell Features","volume":"136","author":"Giacopelli","year":"2020","journal-title":"Blood"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1182\/blood-2014-01-550905","article-title":"Somatic Mutations in MYD88 and CXCR4 Are Determinants of Clinical Presentation and Overall Survival in Waldenstr\u00f6m Macroglobulinemia","volume":"123","author":"Treon","year":"2014","journal-title":"Blood"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ajh.25697","article-title":"Impact of MYD88L265P Mutation Status on Histological Transformation of Waldenstr\u00f6m Macroglobulinemia","volume":"95","author":"Zanwar","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1038\/leu.2013.62","article-title":"MYD88 L265P Is a Marker Highly Characteristic of, but Not Restricted to, Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"27","author":"Giraldo","year":"2013","journal-title":"Leukemia"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.3324\/haematol.2017.186528","article-title":"Highly Sensitive MYD88L265P Mutation Detection by Droplet Digital Polymerase Chain Reaction in Waldenstr\u00f6m Macroglobulinemia","volume":"103","author":"Drandi","year":"2018","journal-title":"Haematologica"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/978-1-0716-2950-5_5","article-title":"MYD88 L265P Mutation Detection by ddPCR: Recommendations for Screening and Minimal Residual Disease Monitoring: ddPCR for Highly Sensitive Detection of MYD88 L265P Mutation","volume":"2621","author":"Drandi","year":"2023","journal-title":"Methods Mol. Biol."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1182\/hematology.2021000312","article-title":"Does MRD Have a Role in the Management of iNHL?","volume":"2021","author":"Giudice","year":"2021","journal-title":"Hematol. Am. Soc. Hematol. Educ. Program"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Xiong, W., Wang, Z., Wang, T., Yu, Y., Huang, Y., Sun, H., Chen, J., Lyu, R., Wang, H., and Yan, Y. (2023). Minimal Residual Disease Status Improved the Response Evaluation in Patients with Waldenstr\u00f6m\u2019s Macroglobulinemia. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1171539"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"13316","DOI":"10.1021\/acs.jmedchem.0c00884","article-title":"Myeloid Differentiation Primary Response Protein 88 (MyD88): The Central Hub of TLR\/IL-1R Signaling","volume":"63","author":"Chen","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/nri3713","article-title":"Assembly and Localization of Toll-like Receptor Signalling Complexes","volume":"14","author":"Gay","year":"2014","journal-title":"Nat. Rev. Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"3896","DOI":"10.1182\/blood-2014-05-573188","article-title":"Activation of Lymphoma-Associated MyD88 Mutations via Allostery-Induced TIR-Domain Oligomerization","volume":"124","author":"Avbelj","year":"2014","journal-title":"Blood"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1093\/jnci\/djt120","article-title":"MyD88 in DNA Repair and Cancer Cell Resistance to Genotoxic Drugs","volume":"105","author":"Kfoury","year":"2013","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1056\/NEJMoa1200710","article-title":"MYD88 L265P Somatic Mutation in Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"367","author":"Treon","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1182\/blood-2012-12-475111","article-title":"A Mutation in MYD88 (L265P) Supports the Survival of Lymphoplasmacytic Cells by Activation of Bruton Tyrosine Kinase in Waldenstr\u00f6m Macroglobulinemia","volume":"122","author":"Yang","year":"2013","journal-title":"Blood"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1111\/bjh.14103","article-title":"Targeting Myddosome Assembly in Waldenstrom Macroglobulinaemia","volume":"177","author":"Liu","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41408-020-0277-6","article-title":"SYK Is Activated by Mutated MYD88 and Drives Pro-Survival Signaling in MYD88 Driven B-Cell Lymphomas","volume":"10","author":"Munshi","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1182\/blood-2016-01-695098","article-title":"HCK Is a Survival Determinant Transactivated by Mutated MYD88, and a Direct Target of Ibrutinib","volume":"127","author":"Yang","year":"2016","journal-title":"Blood"},{"key":"ref_106","first-page":"6203","article-title":"MYD88 Inhibitor ST2825 Suppresses the Growth of Lymphoma and Leukaemia Cells","volume":"37","author":"Shiratori","year":"2017","journal-title":"Anticancer Res."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"djv364","DOI":"10.1093\/jnci\/djv364","article-title":"Targeting of MyD88 Homodimerization by Novel Synthetic Inhibitor TJ-M2010-5 in Preventing Colitis-Associated Colorectal Cancer","volume":"108","author":"Xie","year":"2016","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.1021\/jm200113t","article-title":"Novel Oligonucleotides Containing Two 3\u2032-Ends Complementary to Target mRNA Show Optimal Gene-Silencing Activity","volume":"54","author":"Bhagat","year":"2011","journal-title":"J. Med. Chem."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"iv41","DOI":"10.1093\/annonc\/mdy146","article-title":"Waldenstr\u00f6m\u2019s Macroglobulinaemia: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up","volume":"29","author":"Kastritis","year":"2018","journal-title":"Ann. Oncol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1158\/1078-0432.CCR-15-0646","article-title":"Genomic Landscape of CXCR4 Mutations in Waldenstr\u00f6m Macroglobulinemia","volume":"22","author":"Poulain","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1182\/blood-2011-12-395608","article-title":"WHIM Syndrome Caused by a Single Amino Acid Substitution in the Carboxy-Tail of Chemokine Receptor CXCR4","volume":"120","author":"Liu","year":"2012","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.13200","article-title":"CXCR 4WHIM-like Frameshift and Nonsense Mutations Promote Ibrutinib Resistance but Do Not Supplant MYD 88L265P-directed Survival Signalling in W Aldenstr\u00f6m Macroglobulinaemia Cells","volume":"168","author":"Cao","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1111\/bjh.13897","article-title":"Clonal Architecture of CXCR 4 WHIM-like Mutations in Waldenstr\u00f6m Macroglobulinaemia","volume":"172","author":"Xu","year":"2016","journal-title":"Br. J. Haematol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1111\/bjh.15200","article-title":"Low Levels of von Willebrand Markers Associate with High Serum IgM Levels and Improve with Response to Therapy, in Patients with Waldenstr\u00f6m Macroglobulinaemia","volume":"184","author":"Castillo","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1111\/bjh.13361","article-title":"MYD 88 L265P and CXCR 4 Mutations in Lymphoplasmacytic Lymphoma Identify Cases with High Disease Activity","volume":"169","author":"Schmidt","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1111\/bjh.16088","article-title":"CXCR4 Mutation Subtypes Impact Response and Survival Outcomes in Patients with Waldenstr\u00f6m Macroglobulinaemia Treated with Ibrutinib","volume":"187","author":"Castillo","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0014-5793(98)00359-7","article-title":"Genomic Organization and Promoter Characterization of Human CXCR4 Gene","volume":"426","author":"Caruz","year":"1998","journal-title":"FEBS Lett."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1038\/s41375-020-01102-3","article-title":"CXCR4 in Waldenstr\u00f6m\u2019s Macroglobulinema: Chances and Challenges","volume":"35","author":"Kaiser","year":"2021","journal-title":"Leukemia"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1002\/stem.3174","article-title":"CXCR4 Expression in the Bone Marrow Microenvironment Is Required for Hematopoietic Stem and Progenitor Cell Maintenance and Early Hematopoietic Regeneration after Myeloablation","volume":"38","author":"Singh","year":"2020","journal-title":"Stem Cells Dayt. Ohio"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nature11926","article-title":"CXCL12 in Early Mesenchymal Progenitors Is Required for Haematopoietic Stem-Cell Maintenance","volume":"495","author":"Greenbaum","year":"2013","journal-title":"Nature"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Pawig, L., Klasen, C., Weber, C., Bernhagen, J., and Noels, H. (2015). Diversity and Inter-Connections in the CXCR4 Chemokine Receptor\/Ligand Family: Molecular Perspectives. Front. Immunol., 6.","DOI":"10.3389\/fimmu.2015.00429"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1126\/science.1194396","article-title":"Structures of the CXCR4 Chemokine GPCR with Small-Molecule and Cyclic Peptide Antagonists","volume":"330","author":"Wu","year":"2010","journal-title":"Science"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1038\/leu.2014.187","article-title":"The WHIM-like CXCR4(S338X) Somatic Mutation Activates AKT and ERK, and Promotes Resistance to Ibrutinib and Other Agents Used in the Treatment of Waldenstrom\u2019s Macroglobulinemia","volume":"29","author":"Cao","year":"2015","journal-title":"Leukemia"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bjh.15560","article-title":"TP 53 Mutations Are Associated with Mutated MYD 88 and CXCR 4, and Confer an Adverse Outcome in Waldenstr\u00f6m Macroglobulinaemia","volume":"184","author":"Gustine","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"649","DOI":"10.3324\/haematol.2012.070458","article-title":"Chromosomal Aberrations and Their Prognostic Value in a Series of 174 Untreated Patients with Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"98","author":"Lambert","year":"2013","journal-title":"Haematologica"},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0165-4608(01)00526-X","article-title":"Deletions of 17p13.1 and 13q14 Are Uncommon in Waldenstr\u00f6m Macroglobulinemia Clonal Cells and Mostly Seen at the Time of Disease Progression","volume":"132","author":"Schop","year":"2002","journal-title":"Cancer Genet. Cytogenet."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1182\/bloodadvances.2023010906","article-title":"Biomarker Analysis of the ASPEN Study Comparing Zanubrutinib with Ibrutinib for Patients with Waldenstr\u00f6m Macroglobulinemia","volume":"8","author":"Tam","year":"2024","journal-title":"Blood Adv."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"6325","DOI":"10.1158\/1078-0432.CCR-17-0007","article-title":"TP53 Mutation and Its Prognostic Significance in Waldenstrom\u2019s Macroglobulinemia","volume":"23","author":"Poulain","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"e976","DOI":"10.1097\/HS9.0000000000000976","article-title":"Clonal Relationship and Mutation Analysis in Lymphoplasmacytic Lymphoma\/Waldenstr\u00f6m Macroglobulinemia Associated with Diffuse Large B-Cell Lymphoma","volume":"7","author":"Berendsen","year":"2023","journal-title":"HemaSphere"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2937","DOI":"10.1182\/bloodadvances.2018022962","article-title":"Insights into the Genomic Landscape of MYD88 Wild-Type Waldenstr\u00f6m Macroglobulinemia","volume":"2","author":"Hunter","year":"2018","journal-title":"Blood Adv."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1080\/10428194.2024.2313623","article-title":"Mutational Landscape in Waldenstr\u00f6m Macroglobulinemia Evaluated Using a Next-Generation Sequencing Lymphoma Panel in Routine Clinical Practice","volume":"65","author":"Schejbel","year":"2024","journal-title":"Leuk. Lymphoma"},{"key":"ref_132","first-page":"685","article-title":"Six-Year Follow-up of Phase II Study Exploring Chemo-Free Treatment Association with Idelalisib and Obinutuzumab in Symptomatic Relapsed\/Refractory Patients with Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"104","author":"Tomowiak","year":"2025","journal-title":"Ann. Hematol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"e73","DOI":"10.1111\/bjh.15909","article-title":"Importance of Sequential Analysis of TP53 Variation in Patients with Waldenstr\u00f6m Macroglobulinaemia","volume":"186","author":"Christian","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.3324\/haematol.2017.172718","article-title":"Pattern of Somatic Mutations in Patients with Waldenstr\u00f6m Macroglobulinemia or IgM Monoclonal Gammopathy of Undetermined Significance","volume":"102","author":"Varettoni","year":"2017","journal-title":"Haematologica"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1053\/j.seminhematol.2025.04.001","article-title":"Report of Consensus Panel 3 from the 12th International Workshop on Waldenstrom\u2019s Macroglobulinemia on the Management of Patients with High-Risk Disease","volume":"62","author":"Kapoor","year":"2025","journal-title":"Semin. Hematol."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Garc\u00eda-Sanz, R., and Jim\u00e9nez, C. (2021). Time to Move to the Single-Cell Level: Applications of Single-Cell Multi-Omics to Hematological Malignancies and Waldenstr\u00f6m\u2019s Macroglobulinemia-A Particularly Heterogeneous Lymphoma. Cancers, 13.","DOI":"10.3390\/cancers13071541"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1016\/j.hoc.2018.05.003","article-title":"Genomic Landscape of Waldenstr\u00f6m Macroglobulinemia","volume":"32","author":"Treon","year":"2018","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"e408","DOI":"10.3324\/haematol.2018.190181","article-title":"MYD88 Mutated and Wild-Type Waldenstr\u00f6m\u2019s Macroglobulinemia: Characterization of Chromosome 6q Gene Losses and Their Mutual Exclusivity with Mutations in CXCR4","volume":"103","author":"Guerrera","year":"2018","journal-title":"Haematologica"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/j.1365-2141.2006.06389.x","article-title":"6q Deletion in Waldenstr\u00f6m Macroglobulinemia Is Associated with Features of Adverse Prognosis","volume":"136","author":"Ocio","year":"2007","journal-title":"Br. J. Haematol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"e3210","DOI":"10.1002\/hon.3210","article-title":"Recent Updates in the Indolent Lymphomas: Update on Marginal Zone Lymphoma and Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"42","author":"Amaador","year":"2024","journal-title":"Hematol. Oncol."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2394","DOI":"10.1182\/blood-2021-148095","article-title":"The Genomic Landscape of Waldenstr\u00f6m Macroglobulinemia Reveals Sustained Germinal Center Activity and Late-Developing Copy Number Aberrations","volume":"138","author":"Maclachlan","year":"2021","journal-title":"Blood"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1182\/blood.V126.23.2971.2971","article-title":"Genetic Characterization of Waldenstrom Macroglobulinemia By Next Generation Sequencing: An Analysis of Fouteen Genes in a Series of 61 Patients","volume":"126","author":"Jimenez","year":"2015","journal-title":"Blood"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2008-09-178228","article-title":"microRNA Expression in the Biology, Prognosis, and Therapy of Waldenstr\u00f6m Macroglobulinemia","volume":"113","author":"Roccaro","year":"2009","journal-title":"Blood"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.beha.2016.08.022","article-title":"Epigenomics in Waldenstrom\u2019s Macroglobulinaemia","volume":"29","author":"Sacco","year":"2016","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.1182\/blood-2010-01-265686","article-title":"microRNA-Dependent Modulation of Histone Acetylation in Waldenstrom Macroglobulinemia","volume":"116","author":"Roccaro","year":"2010","journal-title":"Blood"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"e380","DOI":"10.1038\/bcj.2015.106","article-title":"miR-23b\/SP1\/c-Myc Forms a Feed-Forward Loop Supporting Multiple Myeloma Cell Growth","volume":"6","author":"Fulciniti","year":"2016","journal-title":"Blood Cancer J."},{"key":"ref_147","doi-asserted-by":"crossref","unstructured":"Artemaki, P.I., Letsos, P.A., Zoupa, I.C., Katsaraki, K., Karousi, P., Papageorgiou, S.G., Pappa, V., Scorilas, A., and Kontos, C.K. (2021). The Multifaceted Role and Utility of MicroRNAs in Indolent B-Cell Non-Hodgkin Lymphomas. Biomedicines, 9.","DOI":"10.3390\/biomedicines9040333"},{"key":"ref_148","doi-asserted-by":"crossref","unstructured":"Bouyssou, J.M., Liu, C.-J., Bustoros, M., Sklavenitis-Pistofidis, R., Aljawai, Y., Manier, S., Yosef, A., Sacco, A., Kokubun, K., and Tsukamoto, S. (2018). Profiling of Circulating Exosomal miRNAs in Patients with Waldenstr\u00f6m Macroglobulinemia. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0204589"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"100646","DOI":"10.1016\/j.blre.2019.100646","article-title":"Why Do Myeloma Patients Have Bone Disease? A Historical Perspective","volume":"41","author":"Sundan","year":"2020","journal-title":"Blood Rev."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2016.05.001","article-title":"STAT3 Signaling in Immunity","volume":"31","author":"Hillmer","year":"2016","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1038\/icb.2012.17","article-title":"IL-6 Triggers IL-21 Production by Human CD4+ T Cells to Drive STAT3-dependent Plasma Cell Differentiation in B Cells","volume":"90","author":"Diehl","year":"2012","journal-title":"Immunol. Cell Biol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"3774","DOI":"10.1182\/blood-2012-03-419440","article-title":"IL-21 in the Bone Marrow Microenvironment Contributes to IgM Secretion and Proliferation of Malignant Cells in Waldenstrom Macroglobulinemia","volume":"120","author":"Hodge","year":"2012","journal-title":"Blood"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"4389","DOI":"10.1158\/1078-0432.CCR-10-2772","article-title":"FGFR3 Is Overexpressed Waldenstrom Macroglobulinemia and Its Inhibition by Dovitinib Induces Apoptosis and Overcomes Stroma-Induced Proliferation","volume":"17","author":"Azab","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1182\/blood.2020008414","article-title":"Halting the FGF\/FGFR Axis Leads to Antitumor Activity in Waldenstr\u00f6m Macroglobulinemia by Silencing MYD88","volume":"137","author":"Sacco","year":"2021","journal-title":"Blood"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/s41392-021-00828-5","article-title":"Targeting PI3K\/Akt Signal Transduction for Cancer Therapy","volume":"6","author":"He","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1182\/blood-2007-05-092098","article-title":"The Akt Pathway Regulates Survival and Homing in Waldenstrom Macroglobulinemia","volume":"110","author":"Leleu","year":"2007","journal-title":"Blood"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1182\/blood-2009-07-235747","article-title":"Dual Targeting of the PI3K\/Akt\/mTOR Pathway as an Antitumor Strategy in Waldenstrom Macroglobulinemia","volume":"115","author":"Roccaro","year":"2010","journal-title":"Blood"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"e565","DOI":"10.1038\/bcj.2017.40","article-title":"Waldenstrom Macroglobulinemia Cells Devoid of BTKC481S or CXCR4WHIM-like Mutations Acquire Resistance to Ibrutinib through Upregulation of Bcl-2 and AKT Resulting in Vulnerability towards Venetoclax or MK2206 Treatment","volume":"7","author":"Paulus","year":"2017","journal-title":"Blood Cancer J."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1002\/ajh.23814","article-title":"Targeting Survival and Cell Trafficking in Multiple Myeloma and Waldenstrom Macroglobulinemia Using Pan-Class I PI3K Inhibitor, Buparlisib","volume":"89","author":"Sahin","year":"2014","journal-title":"Am. J. Hematol."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"2400","DOI":"10.1158\/1078-0432.CCR-16-1918","article-title":"Prospective, Multicenter Clinical Trial of Everolimus as Primary Therapy in Waldenstrom Macroglobulinemia (WMCTG 09-214)","volume":"23","author":"Treon","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1042\/CS20110340","article-title":"IL-6\/IL-6 Receptor System and Its Role in Physiological and Pathological Conditions","volume":"122","author":"Mihara","year":"2012","journal-title":"Clin. Sci. (Lond.)"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1034\/j.1600-0609.2001.00152.x","article-title":"Serum Levels of IL-6 and Its Soluble Receptor (sIL-6R) in Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"66","author":"Hatzimichael","year":"2001","journal-title":"Eur. J. Haematol."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"5540","DOI":"10.1182\/blood-2011-04-351742","article-title":"Comprehensive Analysis of Tumor Microenvironment Cytokines in Waldenstrom Macroglobulinemia Identifies CCL5 as a Novel Modulator of IL-6 Activity","volume":"118","author":"Elsawa","year":"2011","journal-title":"Blood"},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"21524","DOI":"10.1074\/jbc.M111.234146","article-title":"GLI2 Transcription Factor Mediates Cytokine Cross-Talk in the Tumor Microenvironment","volume":"286","author":"Elsawa","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"2908","DOI":"10.4049\/jimmunol.1402974","article-title":"Modulation of the IL-6 Receptor \u03b1 Underlies GLI2-Mediated Regulation of Ig Secretion in Waldenstr\u00f6m Macroglobulinemia Cells","volume":"195","author":"Jackson","year":"2015","journal-title":"J. Immunol."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"3400","DOI":"10.18632\/oncotarget.26946","article-title":"Targeting IL-6 Receptor Reduces IgM Levels and Tumor Growth in Waldenstr\u00f6m Macroglobulinemia","volume":"10","author":"Han","year":"2019","journal-title":"Oncotarget"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1111\/bjh.18036","article-title":"Diagnosis and Management of Waldenstr\u00f6m Macroglobulinaemia-A British Society for Haematology Guideline","volume":"197","author":"Pratt","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1053\/sonc.2003.50038","article-title":"Prognostic Markers and Criteria to Initiate Therapy in Waldenstrom\u2019s Macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom\u2019s Macroglobulinemia","volume":"30","author":"Kyle","year":"2003","journal-title":"Semin. Oncol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1182\/blood-2016-04-711234","article-title":"Treatment Recommendations from the Eighth International Workshop on Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"128","author":"Leblond","year":"2016","journal-title":"Blood"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1384","DOI":"10.1002\/ajh.25254","article-title":"Predictors of Symptomatic Hyperviscosity in Waldenstr\u00f6m Macroglobulinemia","volume":"93","author":"Abeykoon","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1111\/bjh.14743","article-title":"Serum IgM Level as Predictor of Symptomatic Hyperviscosity in Patients with Waldenstr\u00f6m Macroglobulinaemia","volume":"177","author":"Gustine","year":"2017","journal-title":"Br. J. Haematol."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"e827","DOI":"10.1016\/S2352-3026(20)30224-6","article-title":"Consensus Treatment Recommendations from the Tenth International Workshop for Waldenstr\u00f6m Macroglobulinaemia","volume":"7","author":"Castillo","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_173","first-page":"149","article-title":"Guidelines on the Use of Therapeutic Apheresis in Clinical Practice-Evidence-Based Approach from the Writing Committee of the American Society for Apheresis: The Seventh Special Issue","volume":"31","author":"Schwartz","year":"2016","journal-title":"J. Clin. Apheresis"},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1182\/blood.2022017235","article-title":"How I Use Genomics and BTK Inhibitors in the Treatment of Waldenstr\u00f6m Macroglobulinemia","volume":"143","author":"Treon","year":"2024","journal-title":"Blood"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/j.seminhematol.2023.03.003","article-title":"Report of Consensus Panel 2 from the 11th International Workshop on Waldenstr\u00f6m\u2019s Macroglobulinemia on the Management of Relapsed or Refractory WM Patients","volume":"60","author":"Matous","year":"2023","journal-title":"Semin. Hematol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1001\/jamaoncol.2016.5763","article-title":"Diagnosis and Management of Waldenstr\u00f6m Macroglobulinemia: Mayo Stratification of Macroglobulinemia and Risk-Adapted Therapy (mSMART) Guidelines 2016","volume":"3","author":"Kapoor","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"e299","DOI":"10.1016\/S2352-3026(18)30087-5","article-title":"Treatment and Outcome Patterns in European Patients with Waldenstr\u00f6m\u2019s Macroglobulinaemia: A Large, Observational, Retrospective Chart Review","volume":"5","author":"Buske","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1182\/blood-2015-05-647420","article-title":"Dexamethasone, Rituximab, and Cyclophosphamide as Primary Treatment of Waldenstr\u00f6m Macroglobulinemia: Final Analysis of a Phase 2 Study","volume":"126","author":"Kastritis","year":"2015","journal-title":"Blood"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1634\/theoncologist.2016-0126","article-title":"Evolution of Management and Outcomes in Waldenstr\u00f6m Macroglobulinemia: A Population-Based Analysis","volume":"21","author":"Olszewski","year":"2016","journal-title":"Oncologist"},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1182\/blood-2019-121909","article-title":"Two Years Rituximab Maintenance Vs. Observation after First Line Treatment with Bendamustine Plus Rituximab (B-R) in Patients with Waldenstr\u00f6m\u2019s Macroglobulinemia (MW): Results of a Prospective, Randomized, Multicenter Phase 3 Study (the StiL NHL7-2008 MAINTAIN Trial)","volume":"134","author":"Rummel","year":"2019","journal-title":"Blood"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1016\/S0140-6736(12)61763-2","article-title":"Bendamustine plus Rituximab versus CHOP plus Rituximab as First-Line Treatment for Patients with Indolent and Mantle-Cell Lymphomas: An Open-Label, Multicentre, Randomised, Phase 3 Non-Inferiority Trial","volume":"381","author":"Rummel","year":"2013","journal-title":"Lancet"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/bjh.15718","article-title":"Bendamustine plus Rituximab in Newly-Diagnosed Waldenstr\u00f6m Macroglobulinaemia Patients. A Study on Behalf of the French Innovative Leukaemia Organization (FILO)","volume":"186","author":"Laribi","year":"2019","journal-title":"Br. J. Haematol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1200\/JCO.22.01805","article-title":"Bortezomib-Dexamethasone, Rituximab, and Cyclophosphamide as First-Line Treatment for Waldenstr\u00f6m\u2019s Macroglobulinemia: A Prospectively Randomized Trial of the European Consortium for Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"41","author":"Buske","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1182\/blood-2016-09-742411","article-title":"BDR in Newly Diagnosed Patients with WM: Final Analysis of a Phase 2 Study after a Minimum Follow-up of 6 Years","volume":"129","author":"Gavriatopoulou","year":"2017","journal-title":"Blood"},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1002\/ajh.21788","article-title":"Phase II Trial of Weekly Bortezomib in Combination with Rituximab in Untreated Patients with Waldenstr\u00f6m Macroglobulinemia","volume":"85","author":"Ghobrial","year":"2010","journal-title":"Am. J. Hematol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"3830","DOI":"10.1200\/JCO.2008.20.4677","article-title":"Primary Therapy of Waldenstr\u00f6m Macroglobulinemia with Bortezomib, Dexamethasone, and Rituximab: WMCTG Clinical Trial 05-180","volume":"27","author":"Treon","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1182\/blood-2014-03-566273","article-title":"Carfilzomib, Rituximab, and Dexamethasone (CaRD) Treatment Offers a Neuropathy-Sparing Approach for Treating Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"124","author":"Treon","year":"2014","journal-title":"Blood"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"3247","DOI":"10.1158\/1078-0432.CCR-18-0152","article-title":"Prospective Clinical Trial of Ixazomib, Dexamethasone, and Rituximab as Primary Therapy in Waldenstr\u00f6m Macroglobulinemia","volume":"24","author":"Castillo","year":"2018","journal-title":"Clin. Cancer Res."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"E95","DOI":"10.1002\/ajh.25730","article-title":"CXCR4 Mutational Status Does Not Impact Outcomes in Patients with W Aldenstr\u00f6m Macroglobulinemia Treated with Proteasome Inhibitors","volume":"95","author":"Castillo","year":"2020","journal-title":"Am. J. Hematol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S1470-2045(16)30632-5","article-title":"Ibrutinib for Patients with Rituximab-Refractory Waldenstr\u00f6m\u2019s Macroglobulinaemia (iNNOVATE): An Open-Label Substudy of an International, Multicentre, Phase 3 Trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1182\/blood.2020006844","article-title":"A Randomized Phase 3 Trial of Zanubrutinib vs Ibrutinib in Symptomatic Waldenstr\u00f6m Macroglobulinemia: The ASPEN Study","volume":"136","author":"Tam","year":"2020","journal-title":"Blood"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1056\/NEJMoa1501548","article-title":"Ibrutinib in Previously Treated Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"372","author":"Treon","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"e307","DOI":"10.3324\/haematol.2017.186908","article-title":"Ibrutinib Withdrawal Symptoms in Patients with Waldenstr\u00f6m Macroglobulinemia","volume":"103","author":"Castillo","year":"2018","journal-title":"Haematologica"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1056\/NEJMoa1802917","article-title":"Phase 3 Trial of Ibrutinib plus Rituximab in Waldenstr\u00f6m\u2019s Macroglobulinemia","volume":"378","author":"Dimopoulos","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1002\/ajh.25023","article-title":"Ibrutinib Discontinuation in Waldenstr\u00f6m Macroglobulinemia: Etiologies, Outcomes, and IgM Rebound","volume":"93","author":"Gustine","year":"2018","journal-title":"Am. J. Hematol."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1111\/bjh.18643","article-title":"Dose Reductions in Patients with Waldenstr\u00f6m Macroglobulinaemia Treated with Ibrutinib","volume":"201","author":"Sarosiek","year":"2023","journal-title":"Br. J. Haematol."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"e112","DOI":"10.1016\/S2352-3026(19)30210-8","article-title":"Acalabrutinib Monotherapy in Patients with Waldenstr\u00f6m Macroglobulinemia: A Single-Arm, Multicentre, Phase 2 Study","volume":"7","author":"Owen","year":"2020","journal-title":"Lancet Haematol."},{"key":"ref_198","first-page":"62","article-title":"Preclinical Characterization of Pirtobrutinib, a Highly Selective, Noncovalent (Reversible) BTK Inhibitor","volume":"142","author":"Gomez","year":"2023","journal-title":"Blood"},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1182\/blood-2022-159123","article-title":"Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed\/Refractory Waldenstr\u00f6m Macroglobulinemia: Results from the Phase 1\/2 BRUIN Study","volume":"140","author":"Palomba","year":"2022","journal-title":"Blood"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/bjh.13278","article-title":"The BCL2 Antagonist ABT-199 Triggers Apoptosis, and Augments Ibrutinib and Idelalisib Mediated Cytotoxicity in CXCR4 Wild-Type and CXCR4 WHIM Mutated Waldenstrom Macroglobulinaemia Cells","volume":"170","author":"Cao","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1200\/JCO.21.01194","article-title":"Venetoclax in Previously Treated Waldenstr\u00f6m Macroglobulinemia","volume":"40","author":"Castillo","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2352-3026(16)30166-1","article-title":"Once-Weekly Ofatumumab in Untreated or Relapsed Waldenstr\u00f6m\u2019s Macroglobulinaemia: An Open-Label, Single-Arm, Phase 2 Study","volume":"4","author":"Furman","year":"2017","journal-title":"Lancet Haematol."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"4452","DOI":"10.1182\/blood-2008-04-150854","article-title":"Thalidomide and Rituximab in Waldenstrom Macroglobulinemia","volume":"112","author":"Treon","year":"2008","journal-title":"Blood"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1158\/1078-0432.CCR-08-0862","article-title":"Lenalidomide and Rituximab in Waldenstrom\u2019s Macroglobulinemia","volume":"15","author":"Treon","year":"2009","journal-title":"Clin. Cancer Res."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1053\/sonc.2003.50070","article-title":"2-Chlorodeoxyadenosine Alone and in Combination for Previously Untreated Waldenstrom\u2019s Macroglobulinemia","volume":"30","author":"Weber","year":"2003","journal-title":"Semin. Oncol."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1053\/j.seminhematol.2023.03.005","article-title":"Report of Consensus Panel 1 from the 11th International Workshop on Waldenstrom\u2019s Macroglobulinemia on Management of Symptomatic, Treatment-Na\u00efve Patients","volume":"60","author":"Buske","year":"2023","journal-title":"Semin. Hematol."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1111\/bjh.19920","article-title":"Efficacy and Safety of Bendamustine, Rituximab and Bortezomib Treatment in Relapsed\/Refractory Waldenstrom Macroglobulinaemia: Results of Phase 2 Single-Arm FIL-BRB Trial","volume":"206","author":"Benevolo","year":"2025","journal-title":"Br. J. Haematol."},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/hon.3164_288","article-title":"Indolent Lymphoma: Bendamustine, Rituximab and Acalabrutinib in Waldenstroms Macroglobulinemia (BRAWM)","volume":"41","author":"Berinstein","year":"2023","journal-title":"Hematol. Oncol."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"6324","DOI":"10.1182\/blood-2024-198882","article-title":"Phase II Clinical Study of Zanubrutinib Combined with Bendamustine and Rituximab (ZBR) for Time-Limited Treatment of Waldenstrom Macroglobulinemia","volume":"144","author":"Wenjie","year":"2024","journal-title":"Blood"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00277-018-3311-z","article-title":"Bendamustine and Rituximab (BR) versus Dexamethasone, Rituximab, and Cyclophosphamide (DRC) in Patients with Waldenstr\u00f6m Macroglobulinemia","volume":"97","author":"Paludo","year":"2018","journal-title":"Ann. Hematol."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"4359","DOI":"10.1182\/blood-2024-211804","article-title":"Development and Characterization of a Novel Bifunctional Protac Jh-XIII-05-1 That Shows Potent IRAK1 and IRAK4 Kinase Inhibition and Target Degradation and Is Highly Active in MYD88 Mutated B-Cell Lymphoma Cells Alone and in Combination with BTK- and BCL2- Inhibitors","volume":"144","author":"Hatcher","year":"2024","journal-title":"Blood"},{"key":"ref_212","doi-asserted-by":"crossref","unstructured":"Salvaris, R.T., Brennan, J., and Lewis, K.L. (2025). BTK Is the Target That Keeps on Giving: A Review of BTK-Degrader Drug Development, Clinical Data, and Future Directions in CLL. Cancers, 17.","DOI":"10.3390\/cancers17030557"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1182\/blood-2024-199116","article-title":"Preliminary Efficacy and Safety of the Bruton Tyrosine Kinase Degrader BGB-16673 in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma: Results from the Phase 1 CaDAnCe-101 Study","volume":"144","author":"Thompson","year":"2024","journal-title":"Blood"},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"2804","DOI":"10.1182\/blood.2024024452","article-title":"High Efficacy of CD19 CAR T Cells in Patients with Transformed Waldenstr\u00f6m Macroglobulinemia","volume":"143","author":"Durot","year":"2024","journal-title":"Blood"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/12\/5173\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T04:14:09Z","timestamp":1781064849000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/12\/5173"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,7]]},"references-count":214,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2026,6]]}},"alternative-id":["ijms27125173"],"URL":"https:\/\/doi.org\/10.3390\/ijms27125173","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,7]]}}}